Last reviewed · How we verify
Non-Hodgkin lymphoma
Approved treatments
- Doxorubicin Hydrochloride · Pfizer Inc.
Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Non-Hodgkin lymphoma patent landscape — cliff calendar, originator estates, attackable patents
- Non-Hodgkin lymphoma treatment landscape brief
- Non-Hodgkin lymphoma treatment updates RSS
Frequently asked questions about Non-Hodgkin lymphoma
What drugs treat Non-Hodgkin lymphoma?
Tracked treatments include Doxorubicin Hydrochloride.
What is the treatment for Non-Hodgkin lymphoma?
Standard treatment for Non-Hodgkin lymphoma includes Doxorubicin Hydrochloride. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Non-Hodgkin lymphoma patent cliff · Non-Hodgkin lymphoma CI report
- Treatment: Doxorubicin Hydrochloride · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing